Arterial hypertension in adults. Clinical guidelines 2020
Aim.To study the structure of concomitant cardiovascular and comobid pathology, risk factors in patients with arterial hypertension (AH), coronary heart disease (CHD), with congestive heart failure (CHF) and atrial fibrillation (AF), and to evaluate the quality of diagnostics and treatment in the conditions of real outpatient-polyclinic practice by the Registry in Ryazanskaya region – a RF region with high level of cardiovascular mortality.Material and methods.Into the outpatient-polyclinic registry RECVAZA (Registry of cardiovascular diseases) totally 3690 patients included with AH, CHD, with CHF, AF and their comorbidity, who admitted physicians’ offices in 3 outpatient institutions in Ryazan city: 1047 (28%) males and 2643 (72%) females, mean age 66,1±12,9 y.o.Results.The AHG diagnosis was mentioned in 3648 (98,9%) patients: CHD – in 2548 (69,1%), CHF – 2726 (73,9%), AF – 530 (14,4%). In 79,5% cases there was comorbidity. In general each one patient had 2,6 diagnoses of 4 analyzed. Myocardial infarction and brain stroke were in 11,4% and 9,5% patients’ anamnesis; diabetes – in 19,1%. The level of investigation of patients did not match the expected level with cardiologic pathology. There was non-sufficient amount of investigations and drugs prescribed, especially ACE inhibitors and angiotensine receptor blockers in CHF patients, statins in CHD, beta-blockers in patients with myocardial infarction, anticoagulants in AF, though they had indications. At the moment of Registry, a discount rate of drug price had 16,7% patinets vs. 33,1% in previous years (p<0,0001).Conclusion.RECVAZA results revealed in AH, CHD, CHF and AF patients high prevalence of cardiovascular comorbidity, non-sufficient risk factors evelauation nad accordance to national and international guidelines for treatment – important and real gap for diagnostics and treatment quality improvement in AH, CHD, CHF, AF anf their concomitance.
Aim. To assess age and gender characteristics and determine comorbidity, medication, and outcomes in young ambulatory patients with cardiovascular diseases (CVD) within the framework of an ambulatory prospective registry. Material and methods. The study included 3690 patients with hypertension (HTN), coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and combinations thereof, which applied to 3 Ryazan hospitals. Younger CVD patients (criterion 1-the age of 18-49 years, criterion 2-the age of men 18-54 years old and women 18-64 years old) were compared with older representatives. The presence of CVD and comorbidities, medication, and outcomes over 6 year follow-up were analyzed. Results. The age groups of 18-49 years old and ≥50 years old included 347 (9,4%) and 3343 (90,6%) patients, respectively (men-144 (41,5%) and 902 (27,0%), p<0,0001). According to criterion 2, 1369 (37,1%) people were assigned to the group of young CVD patients (men <55 years old-254 (18,6%) and women <65 years old-1115 (81,4%)). The older group included 2321 people (men-792 (34,1%) and women-1529 (65,9%)). In younger CVD patients (by criteria 1 and 2), the proportion of people with CAD, HF, AF, history of myocardial infarction (MI) and/or stroke, diabetes, respiratory and digestive diseases were significantly lower (p<0,001); there was also a lower proportion of people with cardiovascular multimorbidity. According to criterion 1, the proportion of younger people with ≥2 CVDs was 41%; according to criterion 2-62% (p<0,0001). Among patients <50 years of age, AF and stroke occurred in less than 5% of cases; MI was observed only in men. When using criteria 1 and 2 in patients with early CVD development compared with older patients, there was a larger proportion of obesity cases-19,3% and 20,2% vs 13,8% and 10,8%, respectively (p=0,002 and p=0,019) and according to criterion 2, anemia cases-10,2% and 7,1%, respectively (p=0,004). In younger patients, there were higher proportion of adequate medication-70,9% and 68,8% vs 58,5% and 64,6% (p<0,001), lower mortality-9,8% and 10,4% vs 30,8% and 39,7% (p<0,001). However, reinfarction incidence in men <50 years old was higher-22,7% vs 12,4% (p=0,04). Conclusion. In younger CVD patients compared with older patients, in accordance with criteria 1, there was a large proportion of men; in accordance with criteria 1 and 2-lower incidence of CVD and noncardiac diseases, with the exception of obesity and anemia cases (only by criterion 2). Criterion 1 is more applicable for HTN, CAD, and CHF, while criterion 2-for AF, stroke, and myocardial infarction. Younger CVD patients according to both criteria were characterized by a higher proportion of adequate medication, as well as lower mortality, the incidence of non-fatal stroke and CVD hospitalization. Men with MI history at the age of <50 years have higher reinfarction risk. CVD patients at the age of <50 years old are the target group for the prevention of cardiovascular multimorbidity and its progression.
Disclaimer РThe EAC/RNAS Guidelines represent the views of the EAC and RNAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC and RNAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC/RNAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC/RNAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC/RNAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC/RNAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.Members of the Working Group confirmed the lack of financial support / conflict of interest. In the event of a conflict of interest being reported, the member (s) of the Working Group was (were) excluded from the discussion of sections related to the area of conflict of interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.